Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
Fractyl Health released company-sponsored market research showing strong patient interest in a one-time endoscopic procedure for post-GLP-1 weight maintenance, the use case targeted by its lead candidate Revita. Among nearly 300 surveyed GLP-1 users, 33% preferred stopping medication for a hypothetical procedure; among those who had already discontinued, 84% valued a one-time procedure most. The company estimates about one million U.S. patients discontinue GLP-1s monthly, with 65% of weight-loss users stopping within a year.
Key figures
- Drug Name
- Revita (Revita DMR System)
- Phase Of Trial
- Pivotal (REMAIN-1)
- Surveyed glp1 users
- nearly 300
- Pct preferring procedure
- 33%
- Remain1 co primary pvalue
- 0.0023
- Pct valuing one time procedure
- 84%
- Remain1 weight loss retained 6mo
- approximately 80%
- Pct valuing freedom from medication
- 64%
- Est monthly glp1 discontinuations us
- approximately one million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.